Phase 2
Completed N=36
Cannabidiol in Youth Alcohol Use Disorder
Source: ClinicalTrials.gov NCT05317546 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcomePrimary: Concentrations of Glx (i.e., Glutamate + Glutamine) — 18.76; 18.57 mmol/kg — p=0.33
Summary
The goal of this study is to test cannabidiol (CBD) as a potentially effective candidate medication for youth alcohol use disorder (AUD). To accomplish this goal, this study will use a randomized, double-blind, within-subjects crossover design. In counterbalanced order, 50 youth (ages 16-22) will receive 600 mg of CBD or placebo three hours before a neuroimaging and behavioral assessment paradigm. The total amount of time the participant will be in the study is approximately one month.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Concentrations of Glx (i.e., Glutamate + Glutamine) |
18.76; 18.57 | 0.33 |
| PRIMARY GABA+ |
4.25; 4.22 | 0.75 |
| PRIMARY Alcohol Cue Reactivity Neural Activation |
1.02; 0.87; 0.62; 0.35; 0.53; 0.56 | >0.05 |
| PRIMARY Heart Rate Variability |
0.84; 0.81 | 0.82 |
| PRIMARY PhenX Toolkit Alcohol Urges Questionnaire |
23.18; 21.40; 18.56; 17.63; 16.47; 15.50 | 0.21 |
Eligibility Criteria
Age 16 to 22. Does or does not drink alcohol.
Data sourced from ClinicalTrials.gov (NCT05317546). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.